Cargando…

Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: A protocol for systematic review and meta-analysis

BACKGROUND: Qingshu Yiqi decoction combined with general western medicine are important and prevalent recently treatment method of corona virus disease 2019 (COVID-19) with Delta variant, but the efficacy and safety were not clear. This meta-analysis aims to clarify their clinical efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Yu, Qi, Weiyu, Li, Xin, Yang, Yuying, Cao, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677898/
https://www.ncbi.nlm.nih.gov/pubmed/34918673
http://dx.doi.org/10.1097/MD.0000000000028184
_version_ 1784616238148747264
author Xia, Yu
Qi, Weiyu
Li, Xin
Yang, Yuying
Cao, Jianzhong
author_facet Xia, Yu
Qi, Weiyu
Li, Xin
Yang, Yuying
Cao, Jianzhong
author_sort Xia, Yu
collection PubMed
description BACKGROUND: Qingshu Yiqi decoction combined with general western medicine are important and prevalent recently treatment method of corona virus disease 2019 (COVID-19) with Delta variant, but the efficacy and safety were not clear. This meta-analysis aims to clarify their clinical efficacy and safety thus to provide evidence for clinical application. METHODS: We searched Chinese databases CNKI, Wanfang, VIP and English databases PubMed, Cochrane Library, Embase for the current study. The retrieval time was from the establishment to November, 2021. Literature quality was evaluated according to the bias risk assessment criteria of Cochrane Collaboration network. RevMan 5.3 and Stata 12.0 were used to perform this research. RESULTS: The efficacy and safety of Qingshu Yiqi decoction combined with western medicine for COVID-19 with Delta variant were evaluated in terms of total effective rate, TCM syndrome score, negative conversation rate of viral nucleic acid, disappearance rate of clinical symptoms (such as fever, cough, and fatigue), CT improvement, white blood cell (WBC), lymphocyte (LYM) and adverse reaction rate. CONCLUSION: This study provides reliable evidence-based support for the clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant. PROSPERO REGISTRATION NUMBER: CRD42021271606.
format Online
Article
Text
id pubmed-8677898
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-86778982021-12-20 Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: A protocol for systematic review and meta-analysis Xia, Yu Qi, Weiyu Li, Xin Yang, Yuying Cao, Jianzhong Medicine (Baltimore) 4900 BACKGROUND: Qingshu Yiqi decoction combined with general western medicine are important and prevalent recently treatment method of corona virus disease 2019 (COVID-19) with Delta variant, but the efficacy and safety were not clear. This meta-analysis aims to clarify their clinical efficacy and safety thus to provide evidence for clinical application. METHODS: We searched Chinese databases CNKI, Wanfang, VIP and English databases PubMed, Cochrane Library, Embase for the current study. The retrieval time was from the establishment to November, 2021. Literature quality was evaluated according to the bias risk assessment criteria of Cochrane Collaboration network. RevMan 5.3 and Stata 12.0 were used to perform this research. RESULTS: The efficacy and safety of Qingshu Yiqi decoction combined with western medicine for COVID-19 with Delta variant were evaluated in terms of total effective rate, TCM syndrome score, negative conversation rate of viral nucleic acid, disappearance rate of clinical symptoms (such as fever, cough, and fatigue), CT improvement, white blood cell (WBC), lymphocyte (LYM) and adverse reaction rate. CONCLUSION: This study provides reliable evidence-based support for the clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant. PROSPERO REGISTRATION NUMBER: CRD42021271606. Lippincott Williams & Wilkins 2021-12-17 /pmc/articles/PMC8677898/ /pubmed/34918673 http://dx.doi.org/10.1097/MD.0000000000028184 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 4900
Xia, Yu
Qi, Weiyu
Li, Xin
Yang, Yuying
Cao, Jianzhong
Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: A protocol for systematic review and meta-analysis
title Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: A protocol for systematic review and meta-analysis
title_full Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: A protocol for systematic review and meta-analysis
title_fullStr Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: A protocol for systematic review and meta-analysis
title_full_unstemmed Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: A protocol for systematic review and meta-analysis
title_short Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: A protocol for systematic review and meta-analysis
title_sort clinical efficacy and safety of qingshu yiqi decoction as a complementary and alternative therapy for covid-19 with delta variant: a protocol for systematic review and meta-analysis
topic 4900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677898/
https://www.ncbi.nlm.nih.gov/pubmed/34918673
http://dx.doi.org/10.1097/MD.0000000000028184
work_keys_str_mv AT xiayu clinicalefficacyandsafetyofqingshuyiqidecoctionasacomplementaryandalternativetherapyforcovid19withdeltavariantaprotocolforsystematicreviewandmetaanalysis
AT qiweiyu clinicalefficacyandsafetyofqingshuyiqidecoctionasacomplementaryandalternativetherapyforcovid19withdeltavariantaprotocolforsystematicreviewandmetaanalysis
AT lixin clinicalefficacyandsafetyofqingshuyiqidecoctionasacomplementaryandalternativetherapyforcovid19withdeltavariantaprotocolforsystematicreviewandmetaanalysis
AT yangyuying clinicalefficacyandsafetyofqingshuyiqidecoctionasacomplementaryandalternativetherapyforcovid19withdeltavariantaprotocolforsystematicreviewandmetaanalysis
AT caojianzhong clinicalefficacyandsafetyofqingshuyiqidecoctionasacomplementaryandalternativetherapyforcovid19withdeltavariantaprotocolforsystematicreviewandmetaanalysis